- HK$11.82bn
- HK$17.43bn
- CNY6.06bn
- 24
- 57
- 82
- 56
Annual balance sheet for Luye Pharma, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 5,406 | 5,510 | 5,544 | 6,106 | 6,503 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 1,807 | 2,388 | 2,266 | 2,592 | 4,301 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 9,970 | 10,397 | 10,786 | 10,703 | 13,308 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 4,339 | 4,594 | 4,909 | 5,155 | 6,050 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 20,631 | 22,582 | 24,250 | 25,491 | 29,612 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 7,234 | 7,330 | 9,487 | 8,138 | 10,769 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 12,739 | 14,094 | 14,074 | 12,960 | 15,458 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| ESOP Debt Guarantee | |||||
| Unrealized Gain / Loss | |||||
| Other Equity | |||||
| Total Equity | 7,891 | 8,488 | 10,176 | 12,531 | 14,155 |
| Total Liabilities & Shareholders' Equity | 20,631 | 22,582 | 24,250 | 25,491 | 29,612 |
| Total Common Shares Outstanding |